Intercept Turns To RWE To Confirm Ocaliva’s Benefit In PBC After NASH Complete Response Letter

 
• By Sue Sutter
  
irrigation pivot
Intercept's plan for pivoting to near-term profitability includes discontinuing OCA's development in NASH. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet